TY - JOUR AB - Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression‑free survival (PFS) and to evaluate the indications for lenvatinib treatment in patients with intermediate‑stage HCC refractory to TACE using a data‑mining analysis. A total of 171 patients with intermediate‑stage HCC refractory to TACE were included. All patients were classified into three groups according to their HCC treatment: Lenvatinib (n=45), sorafenib (n=53) and TACE (n=73) groups. PFS time was calculated using the Kaplan‑Meier method and analyzed using a log‑rank test. Factors associated with PFS time were evaluated using multivariate and decision‑tree analyses. The median PFS time was 5.8, 3.2 and 2.4 months in the lenvatinib, sorafenib and TACE groups, respectively (P<0.001). In the Cox regression analysis, lenvatinib treatment and being within the up‑to‑seven criteria were identified as independent factors for PFS (lenvatinib, P<0.0001; within up‑to‑seven, P=0.001). The decision‑tree analysis revealed that patients beyond the up‑to‑seven criteria, treated with lenvatinib and with albumin‑bilirubin (ALBI) grade 1 had a longer PFS time (245.2±107.9 days) than patients beyond the up‑to‑seven criteria, treated with lenvatinib and with ALBI grade 2 (147.1±78.6 days). Additionally, lenvatinib was independently associated with longer PFS time in patients with intermediate‑stage HCC refractory to TACE. Therefore, lenvatinib may be recommended for patients who have intermediate‑stage HCC refractory to TACE, ALBI grade 1 and who are within the up‑to‑seven criteria. AD - Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan Department of Gastroenterology and Hepatology, Yokokura Hospital, Miyama, Fukuoka 839‑0295, Japan Department of Gastroenterology and Hepatology, Yanagawa Hospital, Yanagawa, Fukuoka 832‑0077, Japan Department of Gastroenterology and Hepatology, Iwamoto Internal Medical Clinic, Kitakyushu, Fukuoka 802‑0832, Japan Department of Gastroenterology and Hepatology, Omuta City Hospital, Omuta, Fukuoka 836‑8567, Japan AU - Shimose,Shigeo AU - Kawaguchi,Takumi AU - Tanaka,Masatoshi AU - Iwamoto,Hideki AU - Miyazaki,Ken AU - Moriyama,Etsuko AU - Suzuki,Hiroyuki AU - Niizeki,Takashi AU - Shirono,Tomotake AU - Nakano,Masahito AU - Suga,Hideya AU - Yamaguchi,Taizo AU - Yokokura,Yoshinori AU - Noguchi,Kazunori AU - Koga,Hironori AU - Torimura,Takuji DA - 2020/09/01 DO - 10.3892/ol.2020.11758 EP - 2265 IS - 3 JO - Oncol Lett KW - hepatoma tyrosine‑kinase inhibitor transarterial chemoembolization failure progression‑free survival intermediate-stage hepatocellular carcinoma lenvatinib PY - 2020 SN - 1792-1074 1792-1082 SP - 2257 ST - Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis T2 - Oncology Letters TI - Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis UR - https://doi.org/10.3892/ol.2020.11758 VL - 20 ER -